AR
SRPT icon

Advisory Research’s Sarepta Therapeutics SRPT Stock Holding History

Advisory Research’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,430
Closed -$473K – 486
2023
Q1 		$473K Buy
3,430
+686
+25% +$89K 0.08% 248
2022
Q4 		$356K Buy
+2,744
New +$318K 0.03% 279
2021
Q1 		– Sell
-3,091
Closed -$527K – 390
2020
Q4 		$527K Buy
3,091
+1,495
+94% +$222K 0.04% 256
2020
Q3 		$224K Sell
1,596
-860
-35% -$131K 0.02% 289
2020
Q2 		$394K Buy
+2,456
New +$334K 0.04% 263
2018
Q4 		– Sell
-1,328
Closed -$214K – 395
2018
Q3 		$214K Buy
+1,328
New +$182K ﹤0.01% 354

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisory Research's SRPT Position: Q2 2023 in Review

Advisory Research sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 3,430 shares — an estimated $473K sold.

Advisory Research first reported a position in SRPT in Q3 2018 and held it in 6 quarters. The position peaked at $527K in Q4 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Advisory Research reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Advisory Research sold 3,430 Sarepta Therapeutics shares in Q2 2023, an estimated $473K.
  • Advisory Research first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 6 quarters.
  • Advisory Research's Sarepta Therapeutics position peaked at $527K in Q4 2020.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Advisory Research's 13F filing for Q2 2023, filed 14 Aug 2023.